Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04317287 · ClinicalTrials.gov registry record · NA
To Assess the Efficacy and Safety of the Cardio Formulation in Reducing Oxidized LDL
A NA study, sponsored by Supplement Formulators.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT04317287: Clinical Trial NA study, sponsored by Supplement Formulators.
NCT04317287 is a NA study that was terminated before completion, run by Supplement Formulators. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04317287, a NA study, was terminated before completion, sponsored by Supplement Formulators.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of the Cardio formulation in reducing oxidized LDL \[(Ox LDL (low density lipoprotein)\] in overweight to mildly obese generally healthy adults.
Primary Outcome
Mean or median change in Oxidized LDL from baseline to Day 60
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Cardio formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2021-11-19 |
| Phase | NA |
Why NCT04317287 stopped before completion
NCT04317287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04317287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04317287 about?
NCT04317287 is a clinical study titled "To Assess the Efficacy and Safety of the Cardio Formulation in Reducing Oxidized LDL". The purpose of this study is to assess the efficacy and safety of the Cardio formulation in reducing oxidized LDL \[(Ox LDL (low density lipoprotein)\] in overweight to mildly obese generally healthy adults.
What is the current status of trial NCT04317287?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2019-12-10. Estimated completion is 2021-11-19.
What interventions are being tested in trial NCT04317287?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Cardio formulation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04317287?
This trial is sponsored by Supplement Formulators, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04317287's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI